NeuVax

NeuVax is a peptide vaccine developed by the US biotechnology company Galena Biopharma. It is aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who have reached remission after standard of care treatment, such as surgery, radiation or chemotherapy. As a vaccine, it is intended to protect against a return of the disease rather than to treat an established tumor. The source lead names its purpose and its developer but gives no approval date or trial outcome, so its regulatory status is left for later research. Nothing here is medical advice.